Rheumatoid arthritis

New JAK inhibitor filgotinib shows efficacy in RA: Prof Peter Nash

Evidence is lining up for the likely fourth JAK inhibitor – with filgotinib shown to help treatment-refractory patients with moderate to severe active rheumatoid arthritis achieve a clinical response. A randomised controlled trial, published in JAMA, compared filgotinib at 100mg or 200mg once daily to placebo in 448 adult patients from 114 sites internationally, including ...

Already a member?

Login to keep reading.

© 2021 the limbic